Limits...
Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.

Duarte FB, Gonçalves RP, Barbosa MC, Rocha Filho FD, de Jesus Dos Santos TE, Dos Santos TN, de Vasconcelos PR - Rev Bras Hematol Hemoter (2014)

Bottom Line: However, these patients often show very variable clinical outcomes.At diagnosis, this group of patients also presented clinical features characteristic of a poor prognosis more often than patients who did not express p53.Furthermore, patients expressing p53 had a shorter median survival time compared to those without p53 expression.

View Article: PubMed Central - PubMed

Affiliation: Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil.

No MeSH data available.


Related in: MedlinePlus

Event-free survival curve of patients with low risk myelodysplastic syndrome and positive or negative for p53.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109734&req=5

fig0015: Event-free survival curve of patients with low risk myelodysplastic syndrome and positive or negative for p53.

Mentions: In the group of patients expressing p53, two died and one progressed to AML (progression time: two months). On the other hand, in the group of patients without p53 expression, only one progressed to AML 30 months after diagnosis. The median follow-up time was 31 months after diagnosis, ranging from 9 to 94 months (interquartile range: 16–44.5 months). Analysis of combined, event-free survival (i.e. progression to AML or disease-related death) showed that patients with p53 expression had a significantly lower median survival time compared to patients without p53 expression, 18.5 and 32.5 months, respectively (p-value = 0.046) (Figure 3).


Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.

Duarte FB, Gonçalves RP, Barbosa MC, Rocha Filho FD, de Jesus Dos Santos TE, Dos Santos TN, de Vasconcelos PR - Rev Bras Hematol Hemoter (2014)

Event-free survival curve of patients with low risk myelodysplastic syndrome and positive or negative for p53.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109734&req=5

fig0015: Event-free survival curve of patients with low risk myelodysplastic syndrome and positive or negative for p53.
Mentions: In the group of patients expressing p53, two died and one progressed to AML (progression time: two months). On the other hand, in the group of patients without p53 expression, only one progressed to AML 30 months after diagnosis. The median follow-up time was 31 months after diagnosis, ranging from 9 to 94 months (interquartile range: 16–44.5 months). Analysis of combined, event-free survival (i.e. progression to AML or disease-related death) showed that patients with p53 expression had a significantly lower median survival time compared to patients without p53 expression, 18.5 and 32.5 months, respectively (p-value = 0.046) (Figure 3).

Bottom Line: However, these patients often show very variable clinical outcomes.At diagnosis, this group of patients also presented clinical features characteristic of a poor prognosis more often than patients who did not express p53.Furthermore, patients expressing p53 had a shorter median survival time compared to those without p53 expression.

View Article: PubMed Central - PubMed

Affiliation: Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil.

No MeSH data available.


Related in: MedlinePlus